Cytokines, insulin resistance and arterial wall stiffness in assessing the course of non-alcoholic fatty liver disease
DOI:
https://doi.org/10.14739/2310-1237.2022.1.245985Keywords:
fatty liver, arterial stiffnessAbstract
The progression of non-alcoholic fatty liver disease is associated with an increased prevalence of cardiovascular disease.
Aim: to assess the level of cytokines, insulin resistance, arterial wall stiffness during the progression of hepatic steatosis in patients with non-alcoholic fatty liver disease.
Material and methods. 87 patients with non-alcoholic fatty liver disease were examined. Group I consisted of 14 patients without steatosis, group II – 32 patients with steatosis grade 1; III – 30 patients with steatosis grade 2, IV group – 11 patients with steatosis grade 3. The control group consisted of 30 apparently healthy individuals. Steatometry with a quantitative assessment of the grade of hepatic steatosis was performed using a Soneus P7 ultrasound machine. The content of cytokines (interleukin-6, interleukin-10, TNF-α) was determined using an enzyme-linked immunosorbent assay using a Stat Fax 303 Plus analyzer. The level of insulin resistance was determined using the HOMA-IR index.
Results. The content of interleukin-6 in the blood serum of patients of group IV was significantly increased relative to the level in the control group (by 1.8 times, P < 0.05), patients of group I (by 3.2 times, P < 0.05), II group (by 3.0 times, P < 0.05) and group III (2.3 times, P < 0.05). The level of TNF-α increased with the progression of structural changes in the liver and at grade 4 of steatosis its content was increased by 6.4 times (P < 0.05) relative to the level in the control group, by 8.0 times (P < 0.05) relative to group I patients, by 3.4 times (P < 0.05) – group II patients and by 1.8 times (P < 0.05) – group III patients. An increase in the HOMA-IR index by 3.2 times (P < 0.05) was found in patients with moderate steatosis and 3.9 times (P < 0.05) in patients with severe steatosis compared to controls. A correlation was established between the intima-media thickness of the left common carotid artery and the level of TNF-α (r = 0.438; P = 0.006) and the HOMA-IR index (r = 0.557; P = 0.0008).
Conclusions. In patients with non-alcoholic fatty liver disease with progression of the grade of hepatic steatosis, a significant increase in proinflammatory cytokines, insulin resistance and intima-media thickness of the left common carotid artery was found.
References
Fadieienko, G. D., Kolesnikova, O. V., & Solomenseva, T. A. (2018). Novi mozhlyvosti likuvannia nealkoholnoho steatohepatytu [The new opportunities of treatment of non-alcoholic steatohepatitis]. Suchasna hastroenterolohiia, (1), 53-60. [in Ukrainian].
Sanyal, A. J. (2019). Past, present and future perspectives in nonalcoholic fatty liver disease. Nature reviews. Gastroenterology & hepatology, 16(6), 377-386. https://doi.org/10.1038/s41575-019-0144-8
Younossi, Z. M. (2018). The epidemiology of nonalcoholic steatohepatitis. Clinical Liver Disease, 11(4), 92-94. https://doi.org/10.1002/cld.710
Parkash, O., & Saeed, S. (2018). Molecular Basis for Pathogenesis of Steatohepatitis: Contemporary Understanding and New Insights. In R. Valenzuela (Ed.). Non-alcoholic fatty liver disease – molecular bases, prevention and treatment (pp. 54-54). https://doi.org/10.5772/intechopen.71405
Fang, Y. L., Chen, H., Wang, C. L., & Liang, L. (2018). Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model". World journal of gastroenterology, 24(27), 2974-2983. https://doi.org/10.3748/wjg.v24.i27.2974
Tilg, H., Moschen, A. R., & Roden, M. (2017). NAFLD and diabetes mellitus. Nature reviews. Gastroenterology & hepatology, 14(1), 32-42. https://doi.org/10.1038/nrgastro.2016.147
Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., & Steffen, H. M. (2021). NAFLD and cardiovascular diseases: a clinical review. Clinical research in cardiology, 110(7), 921-937. https://doi.org/10.1007/s00392-020-01709-7
Engin, A. (2017). Non-Alcoholic Fatty Liver Disease. In: A. Engin, A. Engin (Eds.), Obesity and Lipotoxicity. Advances in Experimental Medicine and Biology (Vol. 960, pp. 443-467). Springer, Cham. https://doi.org/10.1007/978-3-319-48382-5_19
Oh, H., Jun, D. W., Saeed, W. K., & Nguyen, M. H. (2016). Non-alcoholic fatty liver diseases: Update on the challenge of diagnosis and treatment. Clinical and Molecular Hepatology, 22(3), 327-335. https://doi.org/10.3350/cmh.2016.0049
Townsend, S. A., & Newsome, P. N. (2017). Mistakes in nonalcoholic fatty liver disease and how to avoid them. UEG Education, 17, 39-41. https://s3-eu-west-1.amazonaws.com/ueg-elearning/ueg-mistakes-series/Mistakes.in.series-102017.NAFLD.pdf
Wieckowska, A., Papouchado, B. G., Li, Z., Lopez, R., Zein, N. N., & Feldstein, A. E. (2008). Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. The American journal of gastroenterology, 103(6), 1372-1379. https://doi.org/10.1111/j.1572-0241.2007.01774.x
Stepanov, Yu. M., Didenko, V. I., Konenko, I. S., & Tatarchuk, O. M. (2019). Vzaiemozviazky mizh ultrazvukovymy, imunolohichnymy zminamy pry prohresuvanni steatozu ta fibrozu pechinky u khvorykh na khronichni dyfuzni zakhvoriuvannia pechinky riznoi etiolohii [Relationships between ultrasonic, immunological changes in the progression of liver steatosis and fibrosis in patients with chronic diffusive liver diseases of various etiologies]. Pathologia, 16(2), 222-230. [in Ukrainian]. https://doi.org/10.14739/2310-1237.2019.2.177167
Raza, S., Rajak, S., Anjum, B., & Sinha, R. A. (2019). Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma. Hepatoma research, 5, 42. https://doi.org/10.20517/2394-5079.2019.014
Stepanov, Y. M., Didenko, V. I., Konenko, I. S., Tatarchuk, O. M., & Petishko, O. P. (2019). Аspects of immunological status and carbon metabolism in patients with non-alcoholic fatty liver disease in correlation with its fibrous transformation. Visnyk problem biolohii i medytsyny, 3(152), 196-200. https://doi.org/10.29254/2077-4214-2019-3-152-196-200
Gubergrits, N. B., & Byelyayeva, N. V. (2019). Sovremennye podkhody k lecheniyu sochetaniya nealkogol'noi zhirovoi bolezni pecheni i serdechno-sosudistykh zabolevanii [Modern approaches to the treatment of combed non-alcoholic fatty liver disease and cardiovascular disease]. Suchasna hastroenterolohiia, (3), 41-48. [in Russian]. https://doi.org/10.30978/MG-2019-3-41
Fadeenko, G. D., Kushnir, I. E., Mozhina, T. L., Chernova, V. M., & Solomentseva, T. A. (2019). Rol syvorotochnykh biomarkerov v diagnostike nealkogolnoi zhirovoi bolezni pecheni [The role of serum biomarkers in the diagnosis of non-alcoholic fatty liver disease]. Suchasna hastroenterolohiia, (3), 58-65. [in Russian]. https://doi.org/10.30978/MG-2019-3-58
Lee, Y. J., Shim, J. Y., Moon, B. S., Shin, Y. H., Jung, D. H., Lee, J. H., & Lee, H. R. (2012). The relationship between arterial stiffness and nonalcoholic fatty liver disease. Digestive diseases and sciences, 57(1), 196-203. https://doi.org/10.1007/s10620-011-1819-3
Sookoian, S., & Pirola, C. J. (2008). Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. Journal of hepatology, 49(4), 600-607. https://doi.org/10.1016/j.jhep.2008.06.012
Downloads
Published
How to Cite
Issue
Section
License
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
